JPMorgan upgraded Fresenius SE to Overweight from Neutral with a price target of EUR 40.10, up from EUR 37.60. The stock’s risk/reward looks “more interesting” with the full exit from the key drags FMC and Vamed, coupled with the inflexion at Kabi and continued delivery at Helios, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FSNUY: